Advertisement

Topics

Novartis pediatric multiple sclerosis drug Gilenya shows significant effect in phase III trial

05:14 EDT 30 Oct 2017 | Pharmaceutical Business Review

Novartis has announced full results from the phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) versus interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

Original Article: Novartis pediatric multiple sclerosis drug Gilenya shows significant effect in phase III trial

NEXT ARTICLE

More From BioPortfolio on "Novartis pediatric multiple sclerosis drug Gilenya shows significant effect in phase III trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...